HUBBLE DRAFT Program Announcement (PA)

The Defense Advanced Research Projects Agency (DARPA) anticipates soliciting proposals under the HUBBLE program to develop an in-silico capability for mapping protein-protein interactions and identifying novel diagnostic and therapeutic targets for traumatic brain injury, with abstract submissions due October 2, 2026. This is a draft Pre-Solicitation Notice; the official Program Announcement will be issued under Notice ID DARPA-PA-26-10, and all information herein is subject to change pending publication on SAM.gov.

The 30-month program is structured as a Phase 1 (12 months) followed by Phase 2 (18 months), with this announcement soliciting Phase 1 proposals only. Phase 1 requires performers to generate an initial protein-protein interaction (PPI) capability capturing approximately 100,000 PPIs modeled over more than 10 conditions across multiple timepoints, cell types, and environmental contexts. Phase 2 scales to a hypercatalog of 10 million unique interactions modeled over 50 or more cellular contexts. Performers must combine in-silico computational approaches with experimental validation; approaches relying exclusively on experimental characterization exceeding 60 percent of budget are out of scope. Technical metrics for Phase 1 include binding energy accuracy within 5 interactors, residence time accuracy exceeding 60 percent, contact residue identity of 0.7, and greater than 90 percent confidence on benchmarking datasets. Multiple awards are anticipated under the Other Transaction for Research authority. All awardees must achieve CMMC Level 1 certification and maintain Government Purpose Rights in developed intellectual property. Selected proposers will be invited to submit Oral Proposal Packages by November 2026.